Cyanocobalamin

维生素B12

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCyanocobalamin
Drug Alias Name氰钴胺素CianocobalaminaCyanocobalaminum氰钴维生素氰钴胺 +[12] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionMethylmalonyl-CoA Mutase stimulants
TargetsMethylmalonyl-CoA Mutase
Therapy Area/IndicationsPlaque psoriasisCNS Embryonal TumorVitamin B 12 Deficiency +[6] 
Global Approved IndicationsVitamin B 12 DeficiencyAnemia, PerniciousAsthenopia
Approved Indications in ChinaVitamin B 12 Deficiency
Original Approved Country/TerritoryCanada
Original Approved Date1951/12/31
Country/TerritoryCanadaUnited StatesTanzania +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesTanta UniversityUniversity Of OsloUniversity Of Bergen +[8] 
Inactive CompaniesEndo Operations LtdUniversity Of Southern CaliforniaNational Cancer Institute +[4] 
Active IndicationsVitamin B 12 DeficiencyAsthenopia
Inactive IndicationsPlaque psoriasisCNS Embryonal TumorAnemia, Pernicious +[4] 

Other Information

ATC CodeB03BA01
Related LinksWikipediaDrugBankKEGG